A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: June 9, 2011
Last updated: January 25, 2016
Last verified: January 2016
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).

Condition Intervention Phase
Major Depressive Disorder
Drug: DVS SR
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Children's Depression Rating Scale, Revised (CDRS-R) total score change from baseline. [ Time Frame: up to 26 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical Global Impression -Improvement (CGI-I) score. [ Time Frame: up to 26 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Impression - Severity (CGI-S) score change from baseline. [ Time Frame: up to 26 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Impression - Improvement (CGI-I) response (score of 1 or 2) [ Time Frame: up to 26 weeks ] [ Designated as safety issue: No ]
  • Remission on the Children's Depression Rating Scale, Revised (CDRS-R) (score <=28) [ Time Frame: up to 26 weeks ] [ Designated as safety issue: No ]

Enrollment: 270
Study Start Date: February 2012
Study Completion Date: October 2015
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Desvenlafaxine Succinate Sustained-Release Drug: DVS SR
Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.


Ages Eligible for Study:   7 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR
  • Willingness and ability to comply with scheduled visits, treatment plan and procedures

Exclusion Criteria:

  • Subject requires precaution against suicide
  • Subject not in a generally healthy condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01371721

  Show 38 Study Locations
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01371721     History of Changes
Other Study ID Numbers: B2061031  3151A6-3357  2008-002064-34 
Study First Received: June 9, 2011
Last Updated: January 25, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Major Depressive Disorder

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders
Desvenlafaxine Succinate
Antidepressive Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin and Noradrenaline Reuptake Inhibitors

ClinicalTrials.gov processed this record on May 24, 2016